SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of TG Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 16, 2022 - (NASDAQ: TGTX)

NEW YORK, Sept. 7, 2022

Shareholders who purchased shares of TGTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/tg-therapeutics-inc-loss-submission-form/?id=31372&from=4

CLASS PERIOD: January 15, 2020 to May 31, 2022

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of the Company's therapeutic product candidates, Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain approval from the U.S. Food and Drug Administration of the Umbralisib marginal zone lymphoma and follicular lymphoma New Drug Application, the Biologics License Application for Ublituximab in combination with Umbralisib, the supplemental New Drug Application for Ublituximab in combination with Umbralisib, or the Ublituximab relapsing forms of multiple sclerosis Biologics License Application in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib's clinical and/or commercial prospects; and (iv) therefore, the Company's public statements were materially false and misleading at all relevant times.

DEADLINE: September 16, 2022 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/tg-therapeutics-inc-loss-submission-form/?id=31372&from=4